Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Express Scripts
AstraZeneca
McKesson
Chinese Patent Office
Moodys
Argus Health
Cipla
Covington

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021520

« Back to Dashboard

NDA 021520 describes SYMBYAX, which is a drug marketed by Lilly and is included in one NDA. It is available from one supplier. Additional details are available on the SYMBYAX profile page.

The generic ingredient in SYMBYAX is fluoxetine hydrochloride; olanzapine. There are twenty-seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride; olanzapine profile page.
Summary for 021520
Tradename:SYMBYAX
Applicant:Lilly
Ingredient:fluoxetine hydrochloride; olanzapine
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021520
Mechanism of ActionSerotonin Uptake Inhibitors
Suppliers and Packaging for NDA: 021520
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520 NDA Eli Lilly and Company 0002-3230 N 0002-3230-30
SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520 NDA Eli Lilly and Company 0002-3231 N 0002-3231-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 25MG BASE;EQ 3MG BASE
Approval Date:Apr 9, 2007TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 25MG BASE;EQ 6MG BASE
Approval Date:Dec 24, 2003TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 50MG BASE;EQ 6MG BASE
Approval Date:Dec 24, 2003TE:ABRLD:Yes

Expired US Patents for NDA 021520

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-002 Dec 24, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-002 Dec 24, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-002 Dec 24, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-001 Apr 9, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Express Scripts
Johnson and Johnson
Accenture
McKinsey
Colorcon
Chinese Patent Office
Queensland Health
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.